Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough
Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading to roughly $0.36 on the cancer data announcement benzinga.com benzinga.com. That rally brought the stock briefly near its 30-day resistance around $0.26 ainvest.com. Before this spike, GNPX had been trading around $0.20. Over the last five trading days the stock was up about 25.6%, although year‐to‐date it was still down roughly 70% benzinga.com. For context, GNPX’s 52-week high is ~$4.09 and its 52-week low is about $0.22 google.com benzinga.com. Trading volumes have surged: approximately 15 million shares traded Oct 14 stockinvest.us. Market data show roughly $11M market cap after the rally benzinga.com. Technical indicators suggest oversold conditions and a short-term bounce, but heavy resistance near $0.27–$0.29 ainvest.com. Backtests warn that past 25–30% spike days have often been followed by pullbacks ainvest.com. In short, GNPX remains a volatile small-cap biotech: the recent surge is notable, but the stock is still far below prior highs.
